Company Profile: smartbax

Background

Overview

Founded in 2021, smartbax is a Munich-based biotechnology company dedicated to developing next-generation antibiotics targeting multi-drug resistant bacteria and challenging biofilms. The company's mission is to create innovative antibacterial compounds with novel mechanisms of action to combat the escalating global threat of antimicrobial resistance (AMR). By focusing on unexploited targets and pioneering approaches, smartbax aims to provide effective solutions where traditional antibiotics have failed.

Key Strategic Focus

Core Objectives and Specialization

smartbax's primary objective is to develop antibiotics with unique, multi-targeted mechanisms of action that address unexploited bacterial targets, thereby reducing the likelihood of resistance development. The company specializes in:

• Enzyme Activation: Utilizing tailored activation of enzymatic pathways to treat biofilms, a condition resistant to classical antibiotics.

• Broad-Spectrum Activity: Targeting both Gram-positive and Gram-negative bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci (VRE), and carbapenem-resistant Enterobacterales (CREB).

Key Technologies Utilized

smartbax employs a platform approach that leverages enzyme activation as a novel feature, enabling the treatment of biofilms and reducing the development of bacterial resistance. This strategy involves:

• Inhibition of Menaquinone Biosynthesis: Disrupting essential electron carriers in bacterial energy metabolism.

• Stimulation of Protein Secretion: Inducing bacterial self-digestion and cell lysis through autolysin homeostasis imbalance.

Primary Markets Targeted

smartbax focuses on addressing infections caused by multi-drug resistant pathogens, particularly in healthcare settings where such infections pose significant challenges. The company's innovative antibiotics aim to serve as effective treatments in areas with high unmet medical needs due to antibiotic resistance.

Financials and Funding

Funding History

As of May 2023, smartbax has raised a total of €1.9 million in funding:

• Pre-Seed Financing: In 2021, the company secured €700,000 from the Boehringer Ingelheim Venture Fund (BIVF).

• Seed Financing: In May 2023, smartbax closed a €1.2 million seed funding round, with investments from BIVF and High-Tech Gründerfonds (HTGF).

Utilization of Capital

The funds are allocated to:

• Advancing small molecule antibiotics through preclinical studies.

• Expanding the scientific team to enhance research platforms.

• Identifying novel solutions against multi-drug resistant pathogens.

Pipeline Development

Key Pipeline Candidates

smartbax is developing a new class of antibiotic compounds with potent activity against Gram-positive, multi-drug resistant bacteria. These compounds exhibit:

• No Detectable Resistance Development: Ensuring sustained efficacy.

• Ability to Kill Persister Cells and Biofilms: Addressing bacterial populations resistant to current antibiotics.

Stages of Development

The lead compound has demonstrated efficacy in animal models and is undergoing preclinical development to further assess its safety and effectiveness.

Target Conditions

The pipeline targets infections caused by:

• MRSA

• VRE

• CREB, including Escherichia coli and Klebsiella pneumoniae

Anticipated Milestones

Key upcoming milestones include:

• Completion of preclinical studies.

• Initiation of clinical trials.

• Regulatory submissions for clinical development.

Technological Platform and Innovation

Proprietary Technologies

smartbax's innovative approach is characterized by:

• Dual-Targeted Mechanism of Action: Simultaneously inhibiting menaquinone biosynthesis and stimulating protein secretion to induce bacterial self-digestion.

• Enzyme Activation Strategy: Tailored activation of enzymatic pathways to effectively treat biofilms.

Significant Scientific Methods

The company employs:

• High-Throughput Screening: To identify compounds with desired antibacterial properties.

• Animal Models: To evaluate the efficacy and safety of lead compounds.

Leadership Team

Executive Profiles

• Dr. Robert Macsics: CEO & Co-Founder

• Background: Holds a PhD in Biochemistry from the Technical University of Munich, an MSc in Pharmacology from the University of Oxford, and an MBA from the Collège des Ingénieurs.

• Role: Oversees scientific and business development, fundraising, and investor relations.

• Dr. Sylvia Varland: Senior Scientist

• Background: PhD in Molecular Biology from the University of Bergen; postdoctoral research at the University of Toronto.

• Role: Leads high-throughput screening efforts.

• Dr. Eric Juskewitz: Senior Scientist

• Background: PhD in Microbiology from the University of Tromsø; experience in antibiotic discovery pipelines.

• Role: Supports discovery and development of compounds.

Executive Advisory Board

• Prof. Dr. Stephan Sieber: Scientific Advisor & Co-Founder

• Background: Chair of Organic Chemistry II at TU Munich; member of the Bavarian Academy of Sciences.

• Role: Provides scientific guidance based on extensive research in antibacterial agents.

• Marco Janezic: Entrepreneurial Advisor & Co-Founder

• Background: Entrepreneur and investor with a focus on life sciences and biotech; Founding Partner of Blue Ribbon Partners.

• Role: Supports company building and business development.

Scientific Advisory Board

• Prof. Dr. Peter Hammann: Scientific Advisor

• Background: Chemist and biochemist with over 30 years of pharmaceutical industry experience; Honorary Professor at the University of Giessen and Saarland University.

• Role: Consults on antibiotic and natural product R&D.

• Prof. Dr. Rolf Müller: Scientific Advisor

• Background: Full Professor for Pharmaceutical Biotechnology at Saarland University; Managing Director of the Helmholtz Institute for Pharmaceutical Research Saarland.

• Role: Provides expertise in microbial natural products and entrepreneurship.

Competitor Profile

Market Insights and Dynamics

The global antibiotics market is experiencing a resurgence in research and development due to the rising threat of antimicrobial resistance. Innovative companies are focusing on novel mechanisms of action to address this challenge.

Competitor Analysis

Key competitors include:

• Adenium Biotech: Develops novel antibiotics for multi-drug resistant bacterial infections.

• Arietis Pharma: Focuses on first-in-class small molecule antibiotics targeting drug-resistant pathogens.

• Glox Therapeutics: Specializes in precision antibiotics to combat antimicrobial resistance.

• Spero Therapeutics: Develops treatments for multi-drug-resistant bacterial infections and rare diseases.

• Amprologix: Works on antibiotics derived from antimicrobial peptides.

These companies are also developing innovative antibiotics with unique mechanisms to address the growing issue of antibiotic resistance.

Strategic Collaborations and Partnerships

smartbax has established significant partnerships to bolster its research and development efforts:

• Boehringer Ingelheim Venture Fund (BIVF): Provided pre-seed and seed funding to support early-stage development.

• High-Tech Gründerfonds (HTGF): Invested in the seed funding round to advance preclinical studies.

These collaborations provide financial support and strategic guidance, enhancing smartbax's capacity to develop innovative antibiotics.

Operational Insights

Strategic Considerations

smartbax differentiates itself through:

• Novel Mechanisms of Action: Targeting unexploited bacterial pathways to reduce resistance development.